Table 2.
Univariate and multivariate analysis of risk factors in relation to DFS in CRLM.
| Parameter | N | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | p value | HR(95%CI) | p value | |||
| Sex | Female | 30 | 1.597(0.950-2.685) | 0.077 | ||
| Male | 55 | Ref | ||||
| Age(years) | <60 | 45 | Ref | |||
| ≥60 | 40 | 1.344(0.822-2.195) | 0.238 | |||
| Viral hepatitis | positive | 9 | 1.119(0.384-2.080) | 0.795 | ||
| negative | 76 | Ref | ||||
| Timing of liver metastases | Synchronous liver metastases | 53 | 2.096(1.210-3.631) | *0.008 | 2.059(1.087-3.901) | *0.027 |
| Metachronous liver metastases | 32 | Ref | ||||
| Primary lesion site | Left hemi-colon | 63 | 0.961(0.551-1.675) | 0.888 | ||
| Right hemi-colon | 22 | Ref | ||||
| Size of primary tumor (mm) | <50 | 53 | Ref | |||
| ≥50 | 32 | 1.359(0.826-2.235) | 0.227 | |||
| Size of metastases (mm) | <30 | 48 | Ref | |||
| ≥30 | 37 | 1.800(1.099-2.947) | *0.020 | 1.441(0.814-2.553) | 0.210 | |
| number of liver metastases | 1 | 52 | Ref | |||
| >1 | 33 | 2.595(1.544-4.360) | *<0.001 | 2.025(1.120-3.662) | *0.020 | |
| sCEA(ng/ml) | <5 | 18 | Ref | |||
| ≥5 | 67 | 1.371(0.753-2.497) | 0.302 | |||
| sCA-199(ng/ml) | <35 | 51 | Ref | |||
| ≥35 | 34 | 3.234(1.914-5.465) | *< 0.001 | 2.914(1.497-5.674) | *0.002 | |
| N stage | N0 | 31 | Ref | |||
| N1-2 | 54 | 1.426(0.848-2.395) | 0.180 | |||
| T stage | T1-2 | 7 | Ref | |||
| T3-4 | 78 | 1.357(0.534-3.450) | 0.521 | |||
| Degree of differentiation | High or Moderately differentiation | 77 | Ref | |||
| Poorly differentiation | 8 | 1.590(0.722-3.502) | 0.250 | |||
| Tumor types | Uplift type | 7 | 1.477(0.908-2.404) | 0.116 | ||
| Ulcer type | 74 | |||||
| invasive | 4 | Ref | ||||
| Lymphovascular invasion | Absent | 40 | Ref | |||
| Present | 45 | 2.610(1.519-4.485) | *0.001 | 2.055(1.183-4.299) | *0.001 | |
| Nerve invasion | Negative | 36 | Ref | |||
| Positive | 49 | 1.752(1.021-3.006) | *0.042 | 1.313(0.729-2.363) | 0.365 | |
| Ki67(%) | <70% | 51 | Ref | |||
| ≥70% | 34 | 2.053(1.160-3.635) | *0.014 | 3.190(1.648-6.175) | *0.001 | |
| MMR | dMMR | 16 | Ref | |||
| pMMR | 69 | 1.864(1.034-3.360) | *0.038 | 1.676(1.772-3.637) | *0.047 | |
| Chemotherapy regimen | 5-Fu-based | 32 | Ref | |||
| Capecitabine -based | 53 | 1.335(0.803-2.219) | 0.265 | |||
* Statistically significant correlation. sCEA, preoperative serum CEA; sAFP, preoperative serum CA199; pMMR, Mismatch Repair Proficiency; dMMR, Mismatch Repair Deficiency; Ref, reference variables. Bold values means statistical differences.